Median progressionsfri overlevelse (defineret som tid til neurologisk progression eller død) var for alle behandlede patienter henholdsvis 77 versus 48 dage for DepoCyte versus uindkapslet cytarabin.
Median progression-free survival (defined as time to neurological progression or death) for all treated patients was 77 versus 48 days for DepoCyte versus unencapsulated cytarabine, respectively.